{
    "clinical_study": {
        "@rank": "60597", 
        "brief_summary": {
            "textblock": "To determine the safety of thymosin alpha 1 given twice weekly in a regimen of daily oral\n      zidovudine (AZT) and biweekly polyethylene glycolated interleukin-2 (PEG IL-2). To determine\n      the effect of thymosin alpha 1 and PEG IL-2 in combination with AZT on immunologic and\n      pharmacokinetic markers.\n\n      AIDS is characterized by diminished T helper cell number and function. Thymosin alpha 1\n      appears to both increase IL-2 receptors on lymphocytes in vitro and enhance lymphocyte\n      maturation in vivo; thus, the drug may further enhance the CD4 T cell levels in patients\n      receiving AZT and PEG IL-2."
        }, 
        "brief_title": "The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "AIDS is characterized by diminished T helper cell number and function. Thymosin alpha 1\n      appears to both increase IL-2 receptors on lymphocytes in vitro and enhance lymphocyte\n      maturation in vivo; thus, the drug may further enhance the CD4 T cell levels in patients\n      receiving AZT and PEG IL-2.\n\n      Patients are stabilized on oral AZT daily for 8 weeks and then begin receiving bolus\n      infusions of PEG IL-2 every other week for at least four doses. Thymosin alpha 1 (given SC)\n      is then added to this regimen twice weekly for 4 weeks. If no significant toxicity occurs,\n      thymosin alpha 1 is increased to and administered along with scheduled doses of PEG IL-2 for\n      an additional 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Prophylactic pentamidine for Pneumocystis carinii.\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  CD4 count > 50 and < 200 cells/mm3.\n\n          -  No active opportunistic infections.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma\n             of the cervix, or Kaposi's sarcoma.\n\n          -  Significant cardiac disease or CNS lesions or other neurologic abnormalities.\n\n          -  Score of > 0.5 on ACTG AIDS Dementia Complex staging.\n\n          -  Major organ allograft.\n\n          -  Intolerance to AZT at 500 mg/day.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antihypertensive medication other than diuretics.\n\n          -  Chemotherapy, hormonal therapy, or other immunotherapy.\n\n          -  Other investigational drugs, agents, or devices.\n\n          -  Beta-blockers.\n\n          -  Non-topical steroids.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic\n             steroids, interferons, interleukins) or other chemotherapy within 30 days prior to\n             study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Transfusion within 4 weeks prior to study entry.\n\n          -  Radiation within 30 days prior to study entry.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001036", 
            "org_study_id": "ACTG 236"
        }, 
        "intervention": [
            {
                "intervention_name": "Thymalfasin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Interleukin-2, Polyethylene Glycolated", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adjuvants, Immunologic", 
                "Thymalfasin", 
                "Interleukin-2", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "T-Lymphocytes", 
            "Polyethylene Glycols", 
            "Interleukin-2", 
            "Drug Therapy, Combination", 
            "Adjuvants, Immunologic", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine", 
            "thymosin alpha(1)"
        ], 
        "lastchanged_date": "July 29, 2008", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "943055107"
                }, 
                "name": "Stanford Univ Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine and Thymosin Alpha 1 in HIV-Positive, Asymptomatic and Symptomatic Individuals", 
        "overall_official": {
            "last_name": "TC Merigan", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8603940", 
            "citation": "Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J Infect Dis. 1996 Apr;173(4):1005-8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001036"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1996"
    }, 
    "geocoordinates": {
        "Stanford Univ Med Ctr": "37.429 -122.169"
    }
}